Top Page
IRLAB Therapeutics AB Class A
(Berlin:IRLAB.A)
IRLAB Therapeutics AB Class A (IRLAB.A) vs. iShares MSCI Sweden ETF (EWD)
IRLAB Therapeutics AB Class A Business Overview & Revenue Model
IRLAB Therapeutics AB Class A Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 94.63M | 5.68M | 61.14M | 207.78M | 300.00K |
| Gross Profit | -92.42M | -122.73M | -111.23M | 168.69M | -1.70M |
| EBITDA | -68.07M | -173.32M | -109.13M | 55.37M | -89.46M |
| Net Income | -83.13M | -177.84M | -114.20M | 51.78M | -91.85M |
Balance Sheet | |||||
| Total Assets | 136.21M | 177.12M | 323.56M | 472.45M | 370.07M |
| Cash, Cash Equivalents and Short-Term Investments | 66.92M | 111.31M | 252.78M | 401.90M | 277.01M |
| Total Debt | 60.42M | 27.57M | 3.98M | 6.60M | 2.93M |
| Total Liabilities | 103.58M | 61.36M | 32.72M | 72.97M | 22.19M |
| Stockholders Equity | 32.63M | 115.76M | 290.83M | 399.48M | 347.88M |
Cash Flow | |||||
| Free Cash Flow | -65.79M | -165.14M | -145.99M | 127.93M | -89.61M |
| Operating Cash Flow | -65.59M | -164.85M | -142.61M | 128.64M | -89.21M |
| Investing Cash Flow | -199.00K | -293.00K | -3.38M | -708.00K | -394.00K |
| Financing Cash Flow | 21.40M | 23.68M | -3.13M | -3.04M | 256.09M |
IRLAB Therapeutics AB Class A Technical Analysis
IRLAB Therapeutics AB Class A Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | kr719.35M | ― | ― | 1.72% | 32.54% | ||
58 Neutral | kr410.63M | ― | -47.73% | ― | 45.52% | 93.35% | |
52 Neutral | kr5.53B | 10.65 | -62.48% | 1.95% | 25.98% | 25.74% | |
48 Neutral | kr404.18M | ― | -18.79% | ― | ― | 21.85% | |
37 Underperform | kr304.08M | ― | -194.31% | ― | 1643.36% | 50.36% | |
32 Underperform | kr407.39M | ― | -205.65% | ― | ― | 24.25% | |
31 Underperform | kr663.79M | ― | -167.55% | ― | ― | 46.67% |
IRLAB Therapeutics AB Class A Corporate Events
IRLAB Therapeutics AB announced the outcome of its rights issue, which raised approximately SEK 115.7 million before costs. The rights issue was subscribed to about 61.1% with and without subscription rights, and the company plans to use the proceeds to strengthen its financial position and prepare for the next stage of its drug development projects, enhancing their appeal for potential partnerships.
IRLAB Therapeutics AB announced the last day for trading subscription rights in their rights issue, which aims to issue new shares of series A with preferential rights for existing shareholders. The rights issue, if fully subscribed, is expected to raise approximately SEK 136 million before costs, with 85% of the issue secured by subscription and guarantee undertakings. Shareholders who do not participate may face dilution but can sell their rights to mitigate financial impact.
IRLAB Therapeutics AB has initiated a rights issue of series A shares, aiming to raise approximately MSEK 136, with the subscription period running from July 3 to July 17, 2025. The rights issue, which is largely secured by subscription and guarantee undertakings, allows existing shareholders to purchase additional shares, although non-participating shareholders may experience dilution of up to 42.9% of their holdings.
IRLAB Therapeutics AB has announced an 85% secured rights issue to raise approximately SEK 136 million, with an extended debt financing of SEK 30 million. The funds will support business development and the advancement of drug candidates, strengthening the company’s financial position and enhancing its appeal in partnership discussions.
IRLAB Therapeutics AB held its Annual General Meeting on June 11, 2025, where several key resolutions were adopted. The meeting approved the financial statements for 2024, decided to carry forward the company’s results without distributing dividends, and re-elected board members and auditors. Additionally, the board’s remuneration was set with a conditional reduction until certain financial targets are met. The meeting also authorized the board to issue new shares or warrants with preferential rights for shareholders.
IRLAB Therapeutics AB announced its participation in the Aktiedagarna event in Stockholm, where CEO Kristina Torfgård will present the company’s developments on June 10. This engagement highlights IRLAB’s active role in the industry, potentially enhancing its visibility and stakeholder engagement as it progresses its Parkinson’s disease treatment pipeline.
IRLAB Therapeutics AB has announced positive results from the second part of its Phase I study for IRL757, a drug candidate aimed at treating apathy in neurodegenerative diseases. The study, funded by The Michael J. Fox Foundation, showed that IRL757 is well absorbed and tolerated, supporting further clinical development. The company has initiated a Phase Ib study in collaboration with The McQuade Center for Strategic Research and Development, with plans to enroll the first patients in late 2025. This development positions IRLAB as a potential leader in addressing apathy, a significant unmet medical need in Parkinson’s and Alzheimer’s diseases.
IRLAB Therapeutics AB announced that CEO Kristina Torfgård will present at the BioStock Global Forum 2025, an event aimed at connecting with potential partners and investors in the pharmaceutical industry. This presentation offers IRLAB a strategic opportunity to expand its network and establish new partnerships, potentially impacting its market positioning and stakeholder engagement.
IRLAB Therapeutics AB has been granted a new patent in the US for the salt form of its drug candidate mesdopetam, which is aimed at treating levodopa-induced dyskinesias in Parkinson’s disease patients. This patent extends the company’s market exclusivity into the 2040s, enhancing the value of mesdopetam and reinforcing IRLAB’s position in the Parkinson’s treatment market.
IRLAB Therapeutics AB reported significant progress in the first quarter of 2025, with positive regulatory feedback from the EMA aligning with the FDA on Phase III for Mesdopetam and promising Phase I results for IRL757. The company also announced a fully funded IRL757 study in Parkinson’s disease and a Phase IIB study with Pirepemat showing a meaningful reduction in fall frequency, strengthening its market position and operational outlook.